OBJECTIVES: This study aims to determine the prevalence and factors associated with unrounded doses ordered via a computerized prescriber order entry (CPOE) system among children during a 1-week reference period. METHODS: This retrospective, cross-sectional study included children younger than 18 years admitted during a 7-day period. An unrounded dose was defined as an unrounded actual dose (eg, dose calculated to the tenths place for non-neonatal intensive care (non-NICU) patients and dose calculated to the hundredth place for NICU patients) or unrounded volume per dose [eg, <0.1 mL for non-NICU patients and <0.01 mL for NICU patients]. A multilevel logistic regression model was used to determine the prevalence and factors associated with unrounded doses via a CPOE system with adjustment for clustering effects. RESULTS: A total of 395 patients were admitted with 391 receiving medications. The overall prevalence of unrounded doses was 30% among the 2426 doses administered. Patients on the NICU team had the highest prevalence of unrounded doses. The odds of an unrounded dose were 4% (adjusted odds ratio, 0.96; 95% confidence interval, 0.94-0.98) lower with each additional kilogram increase in weight after controlling for age, route, scheduled versus as-needed administration, and cluster effects. CONCLUSIONS: The prevalence of unrounded doses was higher than in previous studies. It was higher in smaller children after controlling for age, medication-related variables, and clustering. Future studies should focus on the role of CPOE in preventing unrounded and unmeasurable doses and if these strategies affect clinical outcomes (eg, adverse drug events).
OBJECTIVES: This study aims to determine the prevalence and factors associated with unrounded doses ordered via a computerized prescriber order entry (CPOE) system among children during a 1-week reference period. METHODS: This retrospective, cross-sectional study included children younger than 18 years admitted during a 7-day period. An unrounded dose was defined as an unrounded actual dose (eg, dose calculated to the tenths place for non-neonatal intensive care (non-NICU) patients and dose calculated to the hundredth place for NICU patients) or unrounded volume per dose [eg, <0.1 mL for non-NICU patients and <0.01 mL for NICU patients]. A multilevel logistic regression model was used to determine the prevalence and factors associated with unrounded doses via a CPOE system with adjustment for clustering effects. RESULTS: A total of 395 patients were admitted with 391 receiving medications. The overall prevalence of unrounded doses was 30% among the 2426 doses administered. Patients on the NICU team had the highest prevalence of unrounded doses. The odds of an unrounded dose were 4% (adjusted odds ratio, 0.96; 95% confidence interval, 0.94-0.98) lower with each additional kilogram increase in weight after controlling for age, route, scheduled versus as-needed administration, and cluster effects. CONCLUSIONS: The prevalence of unrounded doses was higher than in previous studies. It was higher in smaller children after controlling for age, medication-related variables, and clustering. Future studies should focus on the role of CPOE in preventing unrounded and unmeasurable doses and if these strategies affect clinical outcomes (eg, adverse drug events).
Authors: H Shonna Yin; Benard P Dreyer; Donna C Ugboaja; Dayana C Sanchez; Ian M Paul; Hannah A Moreira; Luis Rodriguez; Alan L Mendelsohn Journal: Pediatrics Date: 2014-07-14 Impact factor: 7.124
Authors: Kevin B Johnson; Carlton K K Lee; S Andrew Spooner; Coda L Davison; Jill S Helmke; Stuart T Weinberg Journal: Pediatrics Date: 2011-07-25 Impact factor: 7.124
Authors: Kaitlyn Philips; Roy Zhou; Diana S Lee; Christine Marrese; Joanne Nazif; Constance Browne; Mark Sinnett; Steven Tuckman; Kimberly Griffith; Victoria Kiely; Marcia Lutz; Anjali Modi; Michael L Rinke Journal: Hosp Pediatr Date: 2019-10-03
Authors: Kaitlyn Philips; Roy Zhou; Diana S Lee; Christine Marrese; Joanne Nazif; Constance Browne; Mark Sinnett; Steven Tuckman; Anjali Modi; Michael L Rinke Journal: Pediatrics Date: 2021-01-06 Impact factor: 7.124
Authors: Christina E Hoeve; Esther de Vries; Peter G M Mol; Miriam C J M Sturkenboom; Sabine M J M Straus Journal: Drug Saf Date: 2021-01 Impact factor: 5.606
Authors: Thao T Nguyen; Erica Bergeron; Teresa V Lewis; Jamie L Miller; Tracy M Hagemann; Stephen Neely; Peter N Johnson Journal: SAGE Open Med Date: 2020-06-03